RecruitingPhase 1NCT07735377
A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Enrollment
118 participants
Start Date
Aug 26, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This is a phase 1 study to assess the safety and tolerability of SHR-6914 as monotherapy therapy in adult subjects with prostate cancer.
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called SHR-6914 for people with prostate cancer. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years to 80 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSHR-6914
SHR-6914
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07735377
Related Trials
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
NCT075481648 locations
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
NCT060857291 location
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803342 locations
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
NCT056166501 location
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
NCT025942021 location